FDA grants fast track designation to Novavax' H7N9 influenza virus-like particle vaccine
Novavax announced the FDA has granted Fast Track Designation to Novavax' H7N9 Virus-Like Particle Vaccine Candidate adjuvanted with Matrix-M™. The H7N9 VLP is being developed under the company's contract with BARDA to address seasonal influenza and influenza strains with pandemic potential. October 29, 2014